Mithra successfully renegotiates the earnouts relating to its Complex Therapeutics and acquires full licensing and distribution rights for Zoreline®

Liege, Belgium, 24 June 2021 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, is pleased to announce today the successful renegotiation of the earnouts linked to two products of its Complex Therapeutic portfolio: the Zoreline® implant and the Myring® contraceptive hormonal ring

Estelle® Oral Contraceptive Now Available In The United States

21 June 2021, 07:30 CEST – Adelaide, Australia and Liege, Belgium: Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the US commercial launch of Estelle® under the trademark Nextstellis® (3 mg drospirenone and 14.2 mg estetrol (E4) tablets), a new oral contraceptive with a novel estrogen having a unique mechanism of action.

Mithra Completes Recruitment of Covid-19 Phase II Study

Liege, Belgium, 17 June 2021 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has completed recruitment of the Coronesta Phase II, aiming to assess the protective role of Estetrol in Covid-19 infection. Estetrol is a naturally occurring estrogen produced by the human fetus during pregnancy.